Alnylam joins Medtronic, CHDI to treat Huntington's disease
Cambridge biotech Alnylam Pharmaceuticals Inc. is collaborating with Minneapolis-based Medtronic Inc. and California non-profit CHDI Foundation Inc. to advance a drug-device combination treatment of Huntington’s disease, a neurodegenerative genetic disorder.
The treatment, ALN-HTT, is an RNAi therapeutic that targets the huntingtin gene associated with Huntington’s disease. Medtronic developed an implantable infusion system to deliver ALN-HTT. The virtual biotech firm CHDI is focused on the discovery and development of treatments for Huntington’s disease.